Live Breaking News & Updates on Ignacio melero bermejo

Stay updated with breaking news from Ignacio melero bermejo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER" ....

Mccormick-place , Illinois , United-states , Chicago , American , Phil-lhuilier , Ignacio-melero-bermejo , Catalym-gmb , Alison-opalko , Trophic-communications , Oncology-congress , American-society-of-clinical-oncology

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor ....

Zeiten , Mecklenburg-vorpommern , Germany , Chicago , Illinois , United-states , American , Phil-lhuilier , Ignacio-melero-bermejo , Phil-lhuillier , Stefan-klotter , Catalym-gmb

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Illinois , United-states , Chicago , American , Catalym-gmb , Phil-lhuilier , Ignacio-melero-bermejo , Trophic-communications , American-society-of-clinical-oncology , Ted-human-effector-cell-relocation-phase , American-society , Clinical-oncology

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 4 at 9:45 AM CDT CatalYm today announced that the first results from its ongoing Phase 2a trial "GDFATHER-2" ....

Chicago , Illinois , United-states , American , Ignacio-melero-bermejo , Gewinn-nur , Catalym-gmb , Phil-lhuilier , Trophic-communications , American-society-of-clinical-oncology , Ted-human-effector-cell-relocation-phase , American-society

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel ....

Chicago , Illinois , United-states , American , Ignacio-melero-bermejo , American-society-of-clinical-oncology , Ted-human-effector-cell-relocation-phase , American-society , Clinical-oncology , Annual-meeting , Clinica-universidad-de-navarra , Arie-crown-theater